Dr. Reddy's announces the launch of Tobramycin Inhalation Solution
25 June 2019 | News
It is a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution
Dr. Reddy’s Laboratories has announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).
The TOBI® (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health.
Dr. Reddy’s Tobramycin Inhalation Solution, USP is available in a 300 mg/5 mL, single-dose Ampule. Tobi® is a trademark of Mylan.
